Fresh analysis indicates that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds far faster than those who end traditional lifestyle programs.
Research printed in a prominent health publication demonstrates that while obese people often shed substantial amounts of their total mass while on the medication, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals purchasing such treatments must be informed of the potential of quick rebound weight gain when the treatment ends," cautioned expert Dr. Susan Jebb.
Such speed of recovery implies a return to original mass within about a year and a half.
Comparing Therapies
The study, which examined dozens of studies involving over 9,000 of participants, contrasted the outcomes of the injectable medications with older methods.
Scientists emphasize that people who shed pounds through diet and exercise generally have a slower weight regain—around 100 grams monthly—after stopping.
Explaining the Quick Rebound
Experts believe the mode of action of the jabs is key to understanding the amplified weight return.
These medications copy a natural hormone called GLP-1, which helps regulate appetite.
"Artificially providing GLP-1 concentrations far above than normal may cause the body to produce less of its own natural hormone, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in appetite is no longer kept in check, making excessive eating far more likely."
A Chronic Condition?
The NHS recommend the jabs for people with weight-linked medical conditions, alongside prescribed lifestyle changes.
Professionals say that, due to the likelihood of relapse, the treatment is often life-long.
This perspective is echoed by pharmaceutical companies, who say that the findings "underscore the long-term nature of excess weight," similar to managing diseases like high blood pressure.
Patient Experiences
Users who have stopped the jabs report a powerful resurgence of hunger.
"I experienced something that goes on and I was suddenly extremely hungry," described a patient.
The struggle is compounded if individuals have not established permanent dietary or behavioural modifications during treatment.
Widespread Use
Survey data suggest that a significant number of adults in the UK have tried these injections in the past year, with demand remaining high.
- Adoption is higher among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and lasting health benefits likely depends on ongoing behavioural changes.
